Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

Official title

A Randomized Phase III, Global, Multicentre, Open Label Clinical Trial Comparing Venetoclax Azacytidine and Quizartinib Versus Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia Patients Unelegible for Standard Induction Chemotherapy

Overview

The goal of this clinical trial is to learn if Venetoclax+Azacytidine+Quizartinib works better than standard therapy (Venetoclax+Azacytdine) to treat naïve adult patients with acute myeloid leukemia (AML) who are not suitable for standard induction therapy due to age, co-morbidities or other risk factors. The main question it aims to answer is: \- Does the combination of Venetoclax+Azacytidine+Quizartinib show more probability of overall survival than Venetoclax+Azacytdine? Researchers will compare Venetoclax+Azacytidine+Quizartinib to Venetoclax+Azacytdine to see if Venetoclax+Azacytidine+Quizartinib works better than Venetoclax+Azacytdine to treat AML. Participants will be randomized to one of the two treatment arms in a 1:1 ratio, both of which will have treatment cycles of 28 days.

Detailed description

A total of 376 subjects will be randomized to meet scientific and regulatory objectives.

Experimental arm:

* AZA 75 mg/m2 /daily SC, days 1 to 7 in 28-day cycle. * Venetoclax 400 mg/daily oral for 7 days, the same days as AZA. * Quizartinib 60 mg/daily oral in FLT3-ITD negative and 40 mg daily in FLT3-ITD positive patients, days 8 to 21.

Standard arm:

* AZA 75 mg/m2 /daily SC, days 1 to 7 in 28-day cycle. * Venetoclax 400 mg/daily oral for 28 days.ç

Participants will continue their study treatment until documented disease progression, unacceptable toxicity, withdrawal of consent, or the participant meets other protocol criteria for discontinuation or study completion.

Survival information and post treatment follow up will be collected (via telephone calls and/or clinical visits) every 3 months after the last study visit for a period of 2 years after the last patient has been enrolled into the study.

Interventions

• Drug Azacitidine
  Subcutaneous injection during the first 7 days of each 28-day cycle until disease progression or end of study
• Drug Venetoclax
  Oral Venetoclax during the first 7 days of each 28-day cycle until disease progression or end of study
• Drug Quizartinib
  Oral Quizartinib during days 8 to 21 of each 28-day cycle until disease progression or end of study .

Primary outcome measures

• Overall Survival [Time frame: 4 years]

Secondary outcome measures (2)

• Event-free Survival rate [Time frame: 4 years]
• Composite Complete Response (CCR) rate [Time frame: 4 years]

Eligibility criteria

Inclusion criteria

• The subject must have confirmation of AML by 2022 WHO criteria, previously untreated and be ineligible for treatment with a standard cytarabine and anthracycline based induction regimen due to age and/or comorbidities.
• Patients must be considered ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age or co-morbidities defined by the following criteria:

• ≥ 75 years of age;
• or ≥ 18 to 75 years of age with at least one of the following co-morbidities:

• ECOG Performance Status of 2 or 3;
• Cardiac history of cardiac heart failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) >45% and ≤ 55% or chronic stable angina.
• DLCO ≤ 65% or FEV1 ≤ 65% and/or significant history of chronic pulmonary obstructive;
• Creatinine clearance ≥ 30 mL/min to < 50 ml/min (see Appendix 7);
• Moderate hepatic impairment with total bilirubin, SGPT or SGOT > 1.5 to ≤ 3.0 × ULN;
• Non active/controlled prior neoplastic disease;
• Any other patient´s comorbidity or disease condition that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the Clinical Trial Coordinator before study enrollment (e.g, prior neoplastic disease, high-risk cytogenetics). All patients aged less than 60 years old must be reviewed and approved by Clinical Trial Coordinator before study enrollment.
• ECOG performance status ≤2 for patients >75 years, ≤3 for patients ≥ 60 to 75 years of age.
• Male subjects who are sexually active, must agree, from Study Day 1 through at least 120 days after the last dose of study drug, to practice the protocol specified contraception.
• Female subjects must be either postmenopausal for at least 1 year before screening OR permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) or Women of Childbearing Potential (WOCBP) must agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 7 months after the last dose of study drug (female and male condoms should not be used together), or Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[e.g., calendar, ovulation, symptothermal, postovulation methods\] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception). Female subjects of childbearing potential must have negative results for pregnancy test performed and must not be lactating and breastfeeding.
• Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.

Exclusion criteria

• Age <18 years old at screening.
• Subject has received prior treatment with hypomethylating agent, FLT3 or BCL2 inhibitors.
• Confirmed diagnosis of prior myelodysplastic syndrome (MDS) or a myeloproliferative neoplasm (MPN) or MDS/MPNs including CMML, aCML, JMML and others. This exclusion criterion will not be applicable to patients with FLT3 or NPM1 mutations (as per technical sensitivity threshold of local and/or central laboratory), who can be enrolled.
• Genetic diagnosis of acute promyelocytic leukemia.
• Treated (excluding surgery or hormone-therapy) for another malignancy within 6 months before randomization or previously diagnosed with another malignancy and have any evidence of disease which may compromise the administration of investigational treatment schedule.
• Presence of any severe psychiatric disease or physical condition that, according to the physician´s criteria, contraindicates the inclusion of the patient into the clinical trial.
• Serum creatinine ≥ 2.5 mg/dL or creatinine clearance < 30 mL/min.
• Bilirubin >1.5 times, SGPT or SGOT > 3 times the upper normal limit (unless it is attributable to AML activity).
• WBC >25 x 109/L before randomization.
• Contraindications for Azacitidine, Quizartinib or Venetoclax (such as history of hypersensitivity to any excipients in Azacitidine, Quizartinib, or Venetoclax).
• Known central nervous system (CNS) active leukemia, including cerebrospinal fluid positive for AML blasts.
• Prior treatment with any investigational drug or device within 14 days prior to Randomization (within 2 weeks for investigational or approved immunotherapy) or currently participating in other investigational interventional procedures.
• Known uncontrolled or significant cardiovascular disease, including any of the following:

• Bradycardia of less than 50 beats per minute, unless the subject has a pacemaker;
• QTcF interval >450 msec;
• Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);
• Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg;
• History of clinically relevant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes);
• History of second (Mobitz II) or third degree heart block (subjects with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker);
• History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening;
• History of New York Heart Association Class 3 or 4 heart failure;
• Known history of LVEF ≤45%;
• Complete left bundle branch block;
• Severe aortic stenosis
• Prior therapy for AML (except hydroxyurea, or maximum 1 gram/sqm/day per 2 days of cytarabine allowed to control hyperleukocytosis during the screening period).
• Subject must not have consumed grapefruit, grapefruit products, Seville oranges (including marmalade-containing Seville oranges), or star fruit within 3 days before anticipated first dose of Venetoclax and must consent not to consume through the last dose of Venetoclax.
• Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy at physician discretion.
• Known active clinically relevant liver disease (eg, active hepatitis B, or active hepatitis C)
• Known history of human immunodeficiency virus (HIV).
• Uncorrected Grade 3 or 4 hypokalemia, hypomagnesemia or hypocalcemia (Subjects with Grade 1 or 2 electrolyte abnormalities can be enrolled while electrolytes are being corrected).
• Uncontrolled hypothyroidism.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Spain · 51 centers

• Complejo Hospitalario Universitario de A Coruña — Santiago de Compostela
• ICO Hospitalet- Hospital Duran i Reynals — Hospitalet Del Llobregat
• Hospital Mútua de Terrassa — Terrassa
• Complejo Hospitalario de Jaén — Jaén
• Hospital Principe de Asturias — Alcalá de Henares
• Hospital Universitario Infanta Sofía — San Sebastián de los Reyes
• Hospital Regional Universitario de Málaga — Málaga
• Hospital Universitario de Cruces — Barakaldo
• … and 43 more centers

Identifiers

NCT: NCT07478991 · VENP-A-QUI

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗